For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on sale of non-financial asset | - | 0 | 0 | 0 |
| Total revenue | 2,708 | 2,568 | 1,765 | 1,973 |
| Cost of revenue | 598 | 364 | 351 | 326 |
| Research and development | 15,450 | 18,521 | 17,337 | 18,352 |
| General and administrative | 6,966 | 7,382 | 11,586 | 9,527 |
| Total operating expense | -23,014 | -26,267 | -29,274 | -28,205 |
| Loss from operations | -20,306 | -23,699 | -27,509 | -26,232 |
| Interest income | 2,105 | 1,985 | 901 | 665 |
| Interest expense | 2,134 | 2,186 | 2,257 | 2,232 |
| Change in fair value of warrant liability | 80 | -18 | -676 | 2,642 |
| Other income, net | 14 | -7 | -304 | -547 |
| Total other income, net | 65 | -226 | -2,336 | 528 |
| (loss) income before provision for income taxes | -20,241 | -23,925 | -29,845 | -25,704 |
| Provision for income taxes | 0 | 0 | -30 | 37 |
| Net (loss) income | -20,241 | -23,925 | -29,815 | -25,741 |
| Basic EPS | -0.16 | -0.566 | -0.69 | -3.47 |
| Diluted EPS | -0.16 | -0.566 | -0.69 | -3.47 |
| Basic Average Shares | 126,288,723 | 42,292,818* | 43,272,773 | 7,412,990 |
| Diluted Average Shares | 126,288,723 | 42,292,818* | 43,272,773 | 7,412,990 |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)